Seok-Chul Yang
University of California, Los Angeles
11 Papers
39 Citations
Seok-Chul Yang is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cytokine & IL-2 receptor. The author has an hindex of 8, co-authored 11 publications. Previous affiliations of Seok-Chul Yang include Veterans Health Administration.
Chat about Author
Papers
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Felicita Baratelli,Ying Lin,Li Zhu,Seok-Chul Yang,Nathalie Heuzé-Vourc'h,Gang Zeng,Karen L. Reckamp,Mariam Dohadwala,Sherven Sharma,Steven M. Dubinett +9 more
TL;DR: PGE2 enhances the in vitro inhibitory function of human purified CD4+CD25+ T reg cells and induces a regulatory phenotype in CD4-CD25− T cells, the first report indicating that PGE2 can modulate FOXP3 expression and T reg function in human lymphocytes.
Tumor Cyclooxygenase-2/Prostaglandin E2–Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer
Sherven Sharma,Seok-Chul Yang,Li Zhu,Karen L. Reckamp,Brian Gardner,Felicita Baratelli,Min Huang,Raj K. Batra,Steven M. Dubinett +8 more
TL;DR: In vivo inhibition of COX-2/PGE2 suppresses Treg cell activity and enhances antitumor responses, and transfer of Treg cells or administration of PGE2 to mice receiving COx-2 inhibitors reversed these effects.
519
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer
Mariam Dohadwala,Seok-Chul Yang,Jie Luo,Sherven Sharma,Raj K. Batra,Min Huang,Ying Lin,Lee Goodglick,Kostyantyn Krysan,Michael C. Fishbein,Longsheng Hong,Chi Lai,Robert B. Cameron,Robert M. Gemmill,Harry A. Drabkin,Steven M. Dubinett +15 more
TL;DR: It is reported that COX-2-dependent pathways contribute to the modulation of E-cadherin expression in NSCLC and that blocking PGE(2) production or activity may contribute to both prevention and treatment of NSCLCs.
298
SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10
Sherven Sharma,Sherven Sharma,Seok-Chul Yang,Sven Hillinger,Li X. Zhu,Min Huang,Raj K. Batra,Raj K. Batra,Jeff F. Lin,Marie D. Burdick,Robert M. Strieter,Steven M. Dubinett,Steven M. Dubinett +12 more
TL;DR: The findings indicate that the full potency of SLC/CCL21-mediated anti-tumor responses require in part the induction of IFNγ, MIG/CXCL9 and IP-10/CxCL10.
CCL19 reduces tumour burden in a model of advanced lung cancer
Sven Hillinger,Seok-Chul Yang,Raj K. Batra,Robert M. Strieter,Walter Weder,Steven M. Dubinett,Sanjai Sharma +6 more
TL;DR: Findings show that CCL19 may serve as a potential immune stimulator and provide a strong rationale for the evaluation of CCL 19 in cancer immunotherapy, as well as showing a shift towards immune stimulatory molecules with a decrease in the immunosuppressive cytokine TGF-β.